DOCSLIB.ORG

The Letteratura a Tutti a Utomation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Letteratura a Tutti a Utomation THELETTERATURA US A20170296525A1 TUTTIA UTOMATION ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0296525 A1 Moran et al. ( 43 ) Pub . Date : Oct. 19 , 2017 ( 54 ) USE OF COTININE IN TREATING OR (60 ) Provisional application No . 62 /073 ,339 , filed on Oct . PREVENTING NEUROGENESIS DEFICITS 31 , 2014 . AND ENHANCING NEUROGENESIS (71 ) Applicants : Department of Veterans Affairs , Publication Classification Washington , DC (US ) ; University of (51 ) Int . Ci. South Florida , Tampa, FL (US ) A61K 31/ 454 (2006 .01 ) A6IK 31 /55 (2006 . 01 ) (72 ) Inventors : Valentina Echeverria Moran , Largo , A61K 31 / 444 ( 2006 .01 ) FL (US ) ; Doreen Appunn , Tampa , FL .) U . S . CI. (US ) CPC .. .. .. A61K 31/ 454 ( 2013 .01 ) ; A61K 31/ 444 (2013 .01 ) ; A61K 31/ 55 (2013 .01 ) (21 ) Appl. No. : 15 /583 ,937 ( 22 ) Filed : May 1, 2017 (57 ) ABSTRACT A method of inhibiting or treating chemotherapy - induced Related U . S . Application Data cognitive dysfunction comprising administering a therapeu (63 ) Continuation - in - part of application No . PCT/ US15 / tically effective amount of cotinine to a cancer patient 58625 , filed on Nov . 2 , 2015 . experiencing chemotherapy - induced cognitive dysfunction . Percent of Neurogenesis Genes Changed by Cotinine in Forced Swimming Stress 64 % 36 % W Down Up Patent Application Publication Oct. 19 , 2017 Sheet 1 of 10 US 2017 /0296525 A1 Percent of Inflammation and Autoimmunity Genes Changed By Contine in Forced Swimming Stress 39 % n Down Up A 61% Figure 1 . Patent Application Publication Oct. 19 , 2017 Sheet 2 of 10 US 2017 /0296525 A1 Percent of Neurogenesis Genes Changed by Cotinine in Forced Swimming Stress 64 % 36 % A Down Q Up Figure 2 . Patent Application Publication Oct. 19 , 2017 Sheet 3 of 10 US 2017 /0296525 A1 ACH a7nACAR { ? ??? PI3K ? Akt Ser473 . Ser473 Promotes AKD synaptic plasticity , GSK3 Synaptophysiques and mood GSK3P CREB SmartophysinPSD95 stability Impaired synaptic plasticity and depression Figure 3 . Patent Application Publication Oct. 19 , 2017 Sheet 4 of 10 US 2017 /0296525 A1 Tubulin B Tuan NES s NES + Cot= 5 Figure 4 . Patent Application Publication Oct. 19 , 2017 Sheet 5 of 10 US 2017 /0296525 A1 VEGF DNES + Veh DONES - Cot 5 § NormalizedVEGFlevels(%control) q Figure 5 . Patent Application Publication Oct. 19 , 2017 Sheet 6 of 10 US 2017 /0296525 A1 VEGF ** * * Tubulin B NES FS + Veh FS + Cot 5 Figure 6 . Patent Application Publication Oct. 19 , 2017 Sheet 7 of 10 US 2017 /0296525 A1 VEGF recommend NES 0 FS * Veh . FS * Cot 5 CA NormalizedVEGFlevels (%control) * * * Figure 7 . Patent Application Publication Oct. 19 , 2017 Sheet 8 of 10 US 2017 /0296525 A1 NOS2 VEGFA . ERBB2 . EGE CCRZ FOS CCL2 " XXXXX CCL3 CCR4 * * * * * down - regulation · up - regulation regulation coexpression chemicalmodification physical interaction predicted protein interaction Figure 8 . Patent Application Publication Oct. 19 , 2017 Sheet 9 of 10 US 2017 /0296525 A1 Figure 9A - D Fig . 9A Groups Weeks 1 - 2 Weeks 3 - 4 Week 5 CHEMO + Veh CMF Rest Behav . Test - - Veh M oh the others to the team with the CHEMO + Cot 5 CMF Rest Behav . Test Cot 5 Veh + Veh Rest Behav . Test - - - - one that Veb - - - - - - - - - - - - - Veh + Cot 5 Ven Rest Behav. Test Cot 5 Fig . 9B 325 CMF or VehCot 5 or Veh - Veheth Veh H Vehicle Cot 5 For Veh CMF Veh CMF or Ven - CMF + Cot 5 ** * Weight(g) 250 RE Food Supplement 225 _ 5 10 15 20 25 30 days Fig . 9 C Fig . 9 D * * * Rotarod Porsolt' s test moc med 2009 Veh + Veh et nsen ns Veh + Cot 5 * * * * CMF + Veh qowwKill! (sec) CMF Cot 5 Latencytofall (sec) Patent Application Publication Oct. 19 , 2017 Sheet 10 of 10 US 2017 /0296525 A1 Figure 10A - B Fig . 10 A Familiarization ns Vehi Veh Veh Cot 5 CMF Veh DiscriminationIndex CMF + Cot 5 Fig . 10 B Novel Location Recognition ns Veh + Veh O Veh + Cot 5 CMF + Veh DiscriminationIndex Za CMF 4 Cot 5 o US 2017 /0296525 A1 Oct . 19, 2017 USE OF COTININE IN TREATING OR [ 0007 ] These side effects negatively impact their quality of PREVENTING NEUROGENESIS DEFICITS life , impairing home, educational and occupational activities AND ENHANCING NEUROGENESIS and unnecessarily extend disease - related disabilities (Har rington CB , Hansen JA , Moskowitz M , Todd BL , Feuer [ 0001] This application is an 111a application of PCT / stein M (2010 ) It ' s not over when it ' s over : long - term US2015 /058625 , filed Nov. 2 , 2015 , which claims the ben symptoms in cancer survivors a systematic review . Int J efit of U . S . Provisional Application No. 62 /073 , 339, filed on Psychiatry Med 40 ( 2 ) : 163 - 181) . In addition to cognitive Oct . 31 , 2014 , the contents of all of which are incorporated deterioration , people treated with chemotherapy may have herein by reference in their entireties into the present appli higher risk of developing depression due to physical suffer cation . ing or as a complication of therapy itself. For example , [ 0002 ] This invention was made with government support long - term prophylaxis with tamoxifen , a selective estrogen by the United States Department of Veterans Affairs . The receptor modulator commonly used for the hormone recep government has certain rights in the invention . tor- positive breast cancer , has been associated with a higher [0003 ] Throughout this application various publications risk of developing depressive symptoms and cognitive dys are referenced . The disclosures of these publications in their function (Seliktar N , Polek C , Brooks A , Hardie T (2015 ) entireties are hereby incorporated by reference into this Cognition in breast cancer survivors : hormones versus application in order to more fully describe the state of the art depression . Psychooncology 24 ( 4 ) : 402 -407 ) . Currently , to which this invention pertains. there are no completely safe and effective treatments against these side effects ( Joly F , Rigal O , Noal S , Giffard B ( 2011 ) FIELD OF THE INVENTION Cognitive dysfunction and cancer : which consequences in terms of disease management ? Psychooncology 20 ( 12 ) : [0004 ] This invention relates to treatment of chemo 1251 - 1258 ) . Most memory enhancers currently available therapy or stress - related side effects . More specifically, the have significant side effects or limited efficacy in cancer present invention provides therapeutic methods and compo patients . For example , donepezil, a pro - cholinergic drug , has sitions for treating chemotherapy treatment or reducing been studied at the preclinical level , but the attempts to show stress - related neuro - inflammation . efficacy in humans have been unsuccessful ( Fardell J E , Vardy J , Johnston IN , Winocur G ( 2011 ) Chemotherapy and BACKGROUND OF THE INVENTION cognitive impairment: treatment options . Clin Pharmacol [0005 ] Cancer is a group of diseases characterized by Ther 90 ( 3 ) : 366 - 376 ) . uncontrolled growth and dissemination of abnormal cells . It [0008 ] One of the main concerns when selecting an anti was estimated that in 2008 there were 12 . 7 million new depressant is the potential effect that the drug can have on cancer cases worldwide (Belcher E C -GK , Desantis C , the effectiveness or toxicity of the chemotherapeutic regime. Edwards B , Ferlay J , Forman D , Grey N , Harford J , Kramer For example , treatment of depression in a patient treated J , McMikel A , McNeal B , O 'Brien M , Pace L , Parkin M , with tamoxifen can be complicated by drug interactions. Robbins A , Sankaranarayanan R , Sitas F , Slona R , Sullivan Tamoxifen is a mainly inactive pro - drug, necessitating K , Wagner D , Ward E ( 2011 ) Global cancer facts and metabolism by the cytochrome P450 (CYP ) pathway, into its Figures , 2nd edn . American Cancer Society , Atlanta ) . For active metabolites , 4 - hydroxytamoxifen and endoxifen , to many patients afflicted with malignancies , chemotherapy achieve its therapeutic effect. Some antidepressants such as offers the best options for disease control. Though chemo the selective serotonin reuptake inhibitors (SSRI ) paroxetine therapy is an effective way to treat many types of cancer, it and fluoxetine affect the chemotherapy effectiveness by also carries negative side effects . Patients treated with che inhibiting the CYPD6 enzyme which metabolizes tamoxifen motherapy are at an increased risk of altered brain structure to its more active metabolites ( Brauch H , Miirdter T E , and function (de Ruiter M B , Reneman L , Boogerd W , Eichelbaum M , Schwab M ( 2009 ) Pharmacogenomics of Veltman DJ, van Dam F S , Nederveen AJ, Boven E , tamoxifen therapy. Clin Chem 55 ( 10 ) : 1770 - 1782 ) . Schagen S B (2011 ) Cerebral hyporesponsiveness and cog [0009 ] Brain magnetic resonance imaging (MRI ) analysis nitive impairment 10 years after chemotherapy for breast in patients treated with high -dose chemotherapy showed cancer . Hum Brain Mapp 32 ( 8 ) : 1206 - 1219 ) . Neurological white matter lesions that correlated with greater neurocog abnormalities after chemotherapy might result from chemi nitive decline (Fouladi M , Chintagumpala M , Laningham F cal neurotoxicity , indirect oxidative damage, inflammation H , Ashley D , Kellie S J , Langston J W , McCluggage CW , or a type of autoimmune response . Clinical studies indicated Woo S , Kocak M , Krull K , Kun L E , Mulhern RK , Gajjar that up to 70 % of cancer patients who received chemo A (2004 ) White matter lesions detected by magnetic reso therapy experience cognitive impairment and other symp nance imaging after radiotherapy and high - dose chemo toms such as fatigue
Load more

Recommended publications
  • Roger Lee Papke Box 100267 JHM Health Science Center Gainesville, Florida 32610
    CURRICULUM VITAE Roger Lee Papke DEPARTMENT OF PHARMACOLOGY AND THERAPEUTICS UNIVERSITY OF FLORIDA SCHOOL OF MEDICINE Box 100267 J.H.M. Health Science Center Gainesville, Florida 32610 (352) 392-4712, FAX (352) 392-9696 [email protected] BIOGRAPHICAL DATA: Born: October 12, 1953, Kenmore, New York Married: December 24, 1980 to Clare Stokes Citizenship: U. S. A. EDUCATION: Starpoint Central School Pendleton, N. Y. Primary and Secondary N.Y.S. Regents Diploma 1971 New York University Washington Square College of Arts and Sciences 1971 - 1975 Majors in Biology and Classical Civilization Bachelor of Arts awarded May 1975 New York University Graduate school of Arts and Sciences 1975 - 1976 Thesis advisor: Dr. Fleur L. Strand Thesis title: An Alpha Adrenergic Response of Cardiac Muscle at an Alkaline pH Master of Science awarded May 1976 Cornell University Graduate School of Arts and Science 1976-1979: Section of Physiology Graduate Research Assistant in Reproductive Physiology Advisor: Dr. William Hansel Research topic: The endocrine control of delayed implantation in mink Cornell University Graduate School of Arts and Science 1979-1986: Section of Neurobiology and Behavior Thesis Advisor: Dr. Robert Oswald Primary research topic: Pharmacology of nicotinic acetylcholine receptors Thesis Title: The Gating of Single Channel Currents Through the Nicotinic Acetylcholine Receptors of BC3H-1 Cells: Effects of Agonists and Allosteric Ligands Ph.D. conferred January 1987 ACADEMIC APPOINTMENTS: 1987 Postdoctoral Research Associate: Department of Pharmacology,
    [Show full text]
  • Differential Effects of Alkaloids on Memory in Rodents
    www.nature.com/scientificreports OPEN Diferential efects of alkaloids on memory in rodents Patrick M. Callahan1,2, Alvin V. Terry Jr.1,2, Manuel C. Peitsch3, Julia Hoeng3* & Kyoko Koshibu3* Nicotinic acetylcholine receptors (nAChRs) play a critical role in the neuropharmacology of learning and memory. As such, naturally occurring alkaloids that regulate nAChR activity have gained interest for understanding and potentially improving memory function. In this study, we tested the acute efects of three known nicotinic alkaloids, nicotine, cotinine, and anatabine, in suppressing scopolamine-induced memory defcit in rodents by using two classic memory paradigms, Y-maze and novel object recognition (NOR) in mice and rats, respectively. We found that all compounds were able to suppress scopolamine-induced spatial memory defcit in the Y-maze spontaneous alternation paradigm. However, only nicotine was able to suppress the short-term object memory defcit in NOR, despite the higher doses of cotinine and anatabine used to account for their potential diferences in nAChR activity. These results indicate that cotinine and anatabine can uniquely regulate short-term spatial memory, while nicotine seems to have more robust and general role in memory regulation in rodents. Thus, nAChR-activating alkaloids may possess distinct procognitive properties in rodents, depending on the memory types examined. Te cholinergic system of the brain is a critical regulator of attention, memory, and higher-order cognitive processing, and its defcits are central to the etiology of dementia1. As such, nicotinic acetylcholine receptors (nAChRs) have gained much interest as a target of drug development 2. Neuronal nAChRs are pentameric pro- teins composed of various combinations of α (α2–α9) and β (β2–β4) nAChR subunits, diferentially expressed throughout the nervous system.
    [Show full text]
  • Federal Register/Vol. 82, No. 13/Monday, January 23, 2017/Proposed Rules
    8004 Federal Register / Vol. 82, No. 13 / Monday, January 23, 2017 / Proposed Rules DEPARTMENT OF HEALTH AND comment will be made public, you are www.regulations.gov. Submit both HUMAN SERVICES solely responsible for ensuring that your copies to the Division of Dockets comment does not include any Management. If you do not wish your Food and Drug Administration confidential information that you or a name and contact information to be third party may not wish to be posted, made publicly available, you can 21 CFR Part 1132 such as medical information, your or provide this information on the cover [Docket No. FDA–2016–N–2527] anyone else’s Social Security number, or sheet and not in the body of your confidential business information, such comments and you must identify this Tobacco Product Standard for N- as a manufacturing process. Please note information as ‘‘confidential.’’ Any Nitrosonornicotine Level in Finished that if you include your name, contact information marked as ‘‘confidential’’ Smokeless Tobacco Products information, or other information that will not be disclosed except in identifies you in the body of your accordance with 21 CFR 10.20 and other AGENCY: Food and Drug Administration, comments, that information will be applicable disclosure law. For more HHS. posted on http://www.regulations.gov. information about FDA’s posting of • ACTION: Proposed rule. If you want to submit a comment comments to public dockets, see 80 FR with confidential information that you 56469, September 18, 2015, or access SUMMARY: The Food and Drug do not wish to be made available to the the information at: http://www.fda.gov/ Administration (FDA) is proposing a public, submit the comment as a regulatoryinformation/dockets/ tobacco product standard that would written/paper submission and in the default.htm.
    [Show full text]
  • Evaluating the Real-World Effectiveness of Bupropion Versus Varenicline for Smoking Cessation: Exploring the Role of Nicotine Metabolism and Medication Adherence
    Evaluating the Real-World Effectiveness of Bupropion Versus Varenicline for Smoking Cessation: Exploring the Role of Nicotine Metabolism and Medication Adherence By Jiahui Zhang A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Pharmacology and Toxicology University of Toronto © Copyright by Jiahui Zhang (2017) Evaluating the Real-World Effectiveness of Bupropion Versus Varenicline for Smoking Cessation: Exploring the Role of Nicotine Metabolism and Medication Adherence Jiahui Zhang Degree of Master of Science Graduate Department of Pharmacology and Toxicology University of Toronto ABSTRACT Bupropion and varenicline are effective, first-line prescription-only pharmacotherapies for smoking cessation; however, their real-world use is limited by affordability and accessibility. Using a novel internet-based randomized design, we evaluated the real-world effectiveness of mailed bupropion and varenicline, as well as the roles of nicotine metabolism (NMR) and medication adherence, in a sample of interested smokers using web-based recruitment and follow up. Quit rates at end of treatment (EOT) were significantly higher for varenicline (30.2%) compared to bupropion (19.6%). Quit rates at 6 months (14.0%) and 12 months (12.1%) were not significantly different between bupropion and varenicline. Increased medication compliance significantly improved cessation outcomes at EOT. NMR was associated with nicotine dependence. Varenicline benefited Slow Metabolizers of nicotine whilst bupropion benefited Normal Metabolizers. Even though real-world quit rates were comparable to clinical trials, improving medication compliance and implementing personalized pharmacological and behavioral interventions are promising approaches to increase efficacy of smoking cessation pharmacotherapies. ii ACKNOWLEDGEMENTS First and foremost, I would like to express my sincerest appreciation to my supervisor, Dr.
    [Show full text]
  • July 16, 2018 VIA ELECTRONIC SUBMISSION and HAND DELIVERY Division of Dockets Management Food and Drug Administration 5630 Fishe
    Jose Luis Murillo Vice President Regulatory Affairs July 16, 2018 VIA ELECTRONIC SUBMISSION AND HAND DELIVERY Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-N-6189 (83 Fed. Reg. 11,818, March 16, 2018) Advance Notice of Proposed Rulemaking on Tobacco Product Standard for Nicotine Level of Certain Tobacco Products Altria Client Services (“ALCS”), on behalf of Philip Morris USA Inc. (“PM USA”), John Middleton Company (“JMC”), and Sherman Group Holdings LLC and its subsidiaries (“Nat Sherman”),1 submits these comments to the Food and Drug Administration’s (“FDA’s” or the “Agency’s”) Advance Notice of Proposed Rulemaking (“ANPRM”) on a Tobacco Product Standard for Nicotine Level of Certain Tobacco Products. The ANPRM comes within the context of an industry in the midst of transformative change. Cigarette smoking is at historically low levels and continues to decline. At the same time, a new market is emerging in innovative noncombustible tobacco products that are potentially less harmful than cigarettes. There is now a scientific consensus that noncombustible products, like e-vapor, are substantially less risky than conventional cigarettes. It is smoke, and not nicotine, that causes most tobacco- related harm. And adult smokers are increasingly expressing interest in switching from cigarettes to less risky alternatives. We agree that a nicotine product standard of some sort may make sense in a future regulatory system, but this requires the pre-existence of a marketplace with alternative, FDA-authorized, reduced risk products; more information about the relative risks of those products; and a regulatory system that respects the rights of adults to make decisions based on accurate information.
    [Show full text]
  • WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T (51) International Patent Classification: (74) Agents: GILL JENNINGS & EVERY LLP et al; The A61P 25/28 (2006.01) A61K 31/194 (2006.01) Broadgate Tower, 20 Primrose Street, London EC2A 2ES A61P 25/16 (2006.01) A61K 31/205 (2006.01) (GB). A23L 1/30 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 15/05 1898 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 29 June 2015 (29.06.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 141 1570.3 30 June 2014 (30.06.2014) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1412414.3 11 July 2014 ( 11.07.2014) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: MITOCHONDRIAL SUBSTRATE INVEN¬ kind of regional protection available): ARIPO (BW, GH, TION LIMITED [GB/GB]; 39 Glasslyn Road, London GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, N8 8RJ (GB).
    [Show full text]
  • Solanum Alkaloids and Their Pharmaceutical Roles: a Review
    Journal of Analytical & Pharmaceutical Research Solanum Alkaloids and their Pharmaceutical Roles: A Review Abstract Review Article The genus Solanum is treated to be one of the hypergenus among the flowering epithets. The genus is well represented in the tropical and warmer temperate Volume 3 Issue 6 - 2016 families and is comprised of about 1500 species with at least 5000 published Solanum species are endemic to the northeastern region. 1Department of Botany, India Many Solanum species are widely used in popular medicine or as vegetables. The 2Department of Botany, Trivandrum University College, India presenceregions. About of the 20 steroidal of these alkaloid solasodine, which is potentially an important starting material for the synthesis of steroid hormones, is characteristic of *Corresponding author: Murugan K, Plant Biochemistry the genus Solanum. Soladodine, and its glocosylated forms like solamargine, and Molecular Biology Lab, Department of Botany, solosonine and other compounds of potential therapeutic values. India, Email: Keywords: Solanum; Steroidal alkaloid; Solasodine; Hypergenus; Glocosylated; Trivandrum University College, Trivandrum 695 034, Kerala, Injuries; Infections Received: | Published: October 21, 2016 December 15, 2016 Abbreviations: TGA: Total Glycoalkaloid; SGA: Steroidal range of biological activities such as antimicrobial, antirheumatics, Glycoalkaloid; SGT: Sergeant; HMG: Hydroxy Methylglutaryl; LDL: Low Density Lipoprotein; ACAT: Assistive Context Aware Further, these alkaloids are of paramount importance in drug Toolkit; HMDM: Human Monocyte Derived Macrophage; industriesanticonvulsants, as they anti-inflammatory, serve as precursors antioxidant or lead molecules and anticancer. for the synthesis of many of the steroidal drugs which have been used CE: Cholesterol Ester; CCl4: Carbon Tetrachloride; 6-OHDA: 6-hydroxydopamine; IL: Interleukin; TNF: Tumor Necrosis Factor; DPPH: Diphenyl-2-Picryl Hydrazyl; FRAP: Fluorescence treatments.
    [Show full text]
  • Smoking Cessation Prior to Elective Surgery
    2018 OHP Guidelines: Verification of Cessation Smoking Cessation Prior to Elective Surgery Verification of Surgery Smoking Status Cessation Cessation Scheduler Cotinine Current Smoker Options -HPCP code G0432 The scheduler Tobacco Use - Refer to Program -urine or serum sends relevant - Refer to PCP -if positive or if using chart notes and Past 30 days - Do it yourself NRT use one of these PA (prior alternate tests: Anabasine authorization) Recent Quit -HCPC code G0480 request to health Exhaled CO Tobacco Use plan along with: -CPT code 94250 -length of abstinence Past year -on-site equipment -negative lab results -for patients who have quit smoking for at Remote Quit least one year, an Tobacco Use attestation is Over 1 year ago sufficient. Verification of Cessation: Timing issues Verification of abstinence is required for at least four weeks prior to the procedure and requires objective evidence of abstinence from smoking prior to the procedure, which raises timing issues: Procedures Abstinence Requirement Testing required Elective surgical procedures are 1 month One test (urine or serum) 1 month defined as those which are flexible prior to request which starts the in their scheduling because the timeline. If the scheduled date of condition does not pose an procedure is several weeks out, an imminent threat nor does it require additional testing approximately a immediate attention within one week before procedure. month. Lung volume reduction surgery, 6 months Testing 3-4 times during the six bariatric surgery, erectile months is sufficient, again with dysfunction surgery, and spinal evidence of testing at the beginning fusion have 6-month smoking which starts the timeline and abstinence requirements approximately a week before surgery Reproductive procedures (i.e., for contraceptive purposes), cancer-related and diagnostic procedures are excluded from this guideline.
    [Show full text]
  • Bibliography on Smoking and Health. INSTITUTION Public Health Service (DHEW), Rockville, Md
    DOCUMENT RESUME ED 068 857 CG 007 558 TITLE Bibliography on Smoking and Health. INSTITUTION Public Health Service (DHEW), Rockville, Md. National Clearinghouse for Smoking and Health. PUB DATE 71 NOTE 344p. AVAILABLE FROMSuperintendent of Documents, U. S. Government Printing Office, Washington, D. C. 20402 EDRS PRICE MF-S0.65 HC- $13.16 DESCRIPTORS Bibliographic Coupling; *Bibliographies; Booklists; Disease Control; Disease Rate; Diseases; Health; *Health Education; Indexing; Information Retrieval; *Literature Reviews; *Smoking; *Tobacco ABSTRACT This Bibliography includes all of the items added to the Technical Information Center of the National Clearinghouse for Smoking and Health from January through December 1971. The publication is broken down into eleven major categories. These are: (1) chemistry, pharmacology and toxicology; (2) mortality and morbidity;(3) neoplastic diseases;(4) non-neoplastic respiratory diseases; (5) cardiovascular diseases; (6) other diseases and conditions;(7) behavioral and educational research;(8) tobacco economics;(9) bills and legislation; and (10) general references. Also included in this bibliography are a cumulative author and organizational index and a cumulative subject index. U00 1971 NATIONAL CLEARINGHOUSE FOR SMOKING AND HEALTH BIBLIOGRAPHY on SMOKING AND HEALTH U.S. DEPARTMENT OF HEALTII. EDUCATION & WELFARE OFFICE OF EDUCATION THIS DOCUMENT HAS BEEN REPRO- DUCED EXACTLY AS RECEIVED FROM THE PERSON OR ORGANIZATION ORIG INATING IT. POINTS OF VIEW OR OPIN IONS STATED DO NOT NECESSARILY REPRESENT OFFICIAL OFFICE OF EDU- CATION POSITION OR POLICY. U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Health Services and Mental Health Administration FILMED FROM BEST AVAILABLE COPY 1 PREFACE This Bibliography includes all of the items added to theTechnical Information Center of the National Clearinghouse for Smoking and Health fromJanuary through December 1971.
    [Show full text]
  • Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys
    1521-0103/366/2/397–409$35.00 https://doi.org/10.1124/jpet.118.248070 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:397–409, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys Sarah L. Withey,1 Michelle R. Doyle,1,2 Jack Bergman, and Rajeev I. Desai Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts Received January 27, 2018; accepted May 17, 2018 ABSTRACT Evidence suggests that the a4b2, but not the a7, subtype of the except for lobeline, the nicotinic agonists produced either full nicotinic acetylcholine receptor (nAChR) plays a key role in [(1)-epibatidine, (2)-epibatidine, and nicotine] or partial (vare- Downloaded from mediating the behavioral effects of nicotine and related drugs. nicline, cytisine, anabaseine, and isoarecolone) substitution for However, the importance of other nAChR subtypes remains (1)-epibatidine. In interaction studies with antagonists differing unclear. The present studies were conducted to examine the in selectivity, (1)-epibatidine discrimination was substan- involvement of nAChR subtypes by determining the effects of tively antagonized by mecamylamine, slightly attenuated selected nicotinic agonists and antagonists in squirrel monkeys by hexamethonium (peripherally restricted) or dihydro- b a either 1) responding for food reinforcement or 2) discriminating the -erythroidine, and not altered by methyllycaconitine ( 7 jpet.aspetjournals.org nicotinic agonist (1)-epibatidine (0.001 mg/kg) from vehicle. In selective). Varenicline and cytisine enhanced (1)-epibati- food-reinforcement studies, nicotine, (1)-epibatidine, varenicline dine’s discriminative-stimulus effects.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Identifiers: NCT03185546 Date: 12/31/2019 Project 2: The Impact of Cigarette Nicotine Content, E-cigarette Nicotine Content, and E- cigarette Flavoring on Smoking Behavior CENIC II PROJECT 2 The Impact of Cigarette Nicotine Content, E-Cigarette Nicotine Content and E-Cigarette Flavoring on Smoking Behavior Principal Investigator: Eric Donny, Ph.D. Department of Physiology and Pharmacology Date: 4/14/2021 Co-Investigator: Caroline Cobb, PhD – VCU Site Leaders: Eric Donny, PhD – WFSOM Andrew Strasser, PhD – Penn Medical Monitors: Claudia Campos, MD – WFSOM John Spangler, MD - WFSOM Biostatistician: CENIC II Project 2 Joe Koopmeiners, PhD – UMN Principal Investigator Contact Information: Name: Eric Donny, PhD Mailing Address: Dept of Physiology & Pharmacology, 17OCTOBER2019 Page 2 of 66 confidential CENIC II Project 2 Table of Contents Table of Contents...............................................................................................................................3 Abbreviations .....................................................................................................................................4 Study Synopsis ..................................................................................................................................6 1. Background.................................................................................................................................7 2. Study Plan and Procedures ......................................................................................................
    [Show full text]
  • An Access-Dictionary of Internationalist High Tech Latinate English
    An Access-Dictionary of Internationalist High Tech Latinate English Excerpted from Word Power, Public Speaking Confidence, and Dictionary-Based Learning, Copyright © 2007 by Robert Oliphant, columnist, Education News Author of The Latin-Old English Glossary in British Museum MS 3376 (Mouton, 1966) and A Piano for Mrs. Cimino (Prentice Hall, 1980) INTRODUCTION Strictly speaking, this is simply a list of technical terms: 30,680 of them presented in an alphabetical sequence of 52 professional subject fields ranging from Aeronautics to Zoology. Practically considered, though, every item on the list can be quickly accessed in the Random House Webster’s Unabridged Dictionary (RHU), updated second edition of 2007, or in its CD – ROM WordGenius® version. So what’s here is actually an in-depth learning tool for mastering the basic vocabularies of what today can fairly be called American-Pronunciation Internationalist High Tech Latinate English. Dictionary authority. This list, by virtue of its dictionary link, has far more authority than a conventional professional-subject glossary, even the one offered online by the University of Maryland Medical Center. American dictionaries, after all, have always assigned their technical terms to professional experts in specific fields, identified those experts in print, and in effect held them responsible for the accuracy and comprehensiveness of each entry. Even more important, the entries themselves offer learners a complete sketch of each target word (headword). Memorization. For professionals, memorization is a basic career requirement. Any physician will tell you how much of it is called for in medical school and how hard it is, thanks to thousands of strange, exotic shapes like <myocardium> that have to be taken apart in the mind and reassembled like pieces of an unpronounceable jigsaw puzzle.
    [Show full text]